Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Higher silicone breast implant rupture rate shown in recent data, FDA tells Rep. Shays.

This article was originally published in The Gray Sheet

Executive Summary

SILICONE BREAST IMPLANT RUPTURE RATE APPEARS "SIGNIFICANTLY HIGHER" than previously has been reported, FDA says in a May 25 response to an inquiry from House Government Reform/Human Resources Subcommittee Chairman Christopher Shays (R-Conn.). In a May 10 letter to FDA Commissioner David Kessler, Shays asked the agency to comment on recent clinical studies on the safety of silicone breast implants. Based on a review of recent epidemiological studies, FDA concludes, "There is now data to suggest that the failure rate due to implant rupture may be significantly higher than previously described, and/or may increase significantly with time."

You may also be interested in...

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.

People On The Move: Appointments At Stada, PGEU, And UK Health Claims Committee

Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts